?
Deine Einschätzung
Ultragenyx Pharmaceutical Inc. Aktie
Was spricht für und gegen Ultragenyx Pharmaceutical Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Ultragenyx Pharmaceutical Inc. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 0,80 % | -7,37 % | -13,65 % | -41,46 % | 12,20 % | -60,40 % | -75,68 % |
| Ligand Pharmaceuticals | 0,97 % | 1,98 % | 4,57 % | 120,32 % | 24,10 % | 202,94 % | 122,27 % |
| United Therapeutics | -0,46 % | -1,20 % | -6,05 % | 66,92 % | 11,61 % | 133,43 % | 228,90 % |
| Ionis Pharmaceuticals Inc. | 0,22 % | -1,46 % | 0,47 % | 108,65 % | -4,91 % | 59,40 % | 127,70 % |
Kommentare
News
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
On May 14, 2026, Krensavage Asset Management disclosed it bought 241,245 shares of Ultragenyx Pharmaceutical (NASDAQ:RARE), an estimated $5.43 million trade based on quarterly average pricing.
Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today
While Ultragenyx Pharmaceutical (NASDAQ: RARE) provided the market with disappointing news yesterday -- shares plunged more than 42% -- it appears that investors aren't completely writing off the
Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today
Heading into 2026 on an inauspicious note, Ultragenyx Pharmaceuticals (NASDAQ: RARE), a pharmaceutical company specializing in treatments for rare and ultra-rare genetic diseases, announced



